Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214687 | 1.00 | CTSB (0.41) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL2214691 | 1.00 | CTSB (0.41) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL2214696 | 1.00 | CTSB (0.41) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL8171007 | 0.93 | CTSB (0.38) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL8278237 | 0.92 | CTSB (0.40) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL8239469 | 0.92 | CTSB (0.41) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL995545 | 0.92 | CTSB (0.41) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL995543 | 0.92 | CTSB (0.41) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL8382394 | 0.91 | CTSB (0.41) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL4212027 | 0.89 | ADRB3 (0.43) | CTSBCTSSCYP3A4ADRB3ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220520-A1 | BIOAVAILABLE COMBINATIONS FOR HCV TREATMENT | JANSSEN SCIENCES IRELAND UC (IE) | 2012-08-30 | — | — | US | disclosed |
| US-7989471-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-02 | — | — | US | disclosed |
| US-7989471-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-02 | — | — | US | disclosed |
| US-20100240698-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240698-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2010-09-23 | — | — | US | disclosed |
| WO-2008046860-A2 | BIOAVAILABLE COMBINATIONS FOR HCV TREATMENT | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220520-A1 | BIOAVAILABLE COMBINATIONS FOR HCV TREATMENT | HAVCR2, CYP7A1, CYP3A4 | CTSB 111/4885CTSS 206/4885CYP3A4 3/4885 |
| US-20100240698-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2B6, SRD5A1, NR5A2 | CTSB 4505/4885CTSS 3796/4885CYP3A4 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.